Employers search
About Us
At the forefront of innovation: Leveraging the power of alpha-particles
Perspective Therapeutics is a clinical-stage, radiopharmaceutical company that is pioneering innovative treatments for cancers. The Company’s proprietary technology utilizes the alpha emitting isotope Pb-212 to deliver powerful radiation directly to cancer cells via high-affinity targeting peptides.
These radiotherapies are developed as theranostic platforms by incorporating the radiotracer Pb-203 for imaging into the same targeting peptides. This theranostic approach enables physicians to confirm tumor target expression and tissue distribution prior to therapy, with the potential to select eligible patients and minimize toxicity associated with other types of cancer treatments.